Janus Henderson Group PLC Nektar Therapeutics Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $29,521 - $145,303	46,128 Added 126.46%	82,603 $57,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $2 - $4	-1 Reduced -0.0%	36,475 $82,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $212 - $359	70 Added 0.19%	36,476 $117,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $145 - $283	-46 Reduced 0.13%	36,406 $138,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $7,816 - $25,779	-1,879 Reduced 4.9%	36,452 $196,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $124,133 - $211,015	11,462 Added 42.66%	38,331 $518,000
Q3 2021 Nov 16, 2021	BUY	$13.07 - $18.84 $351,177 - $506,211	26,869 New	26,869 $482,000
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $971,805 - $1.2 Million	-58,826 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $974,158 - $1.5 Million	58,826 New	58,826 $1.18 Million
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $785,961 - $948,436	-49,839 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $229,671 - $343,192	-13,844 Reduced 21.74%	49,839 $827,000
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $72,986 - $101,471	-4,329 Reduced 6.37%	63,683 $1.48 Million
Q1 2020 May 14, 2020	SELL	$14.47 - $27.96 $15.5 Million - $29.9 Million	-1,069,275 Reduced 94.02%	68,012 $1.21 Million
Q4 2019 Feb 18, 2020	SELL	$15.87 - $23.12 $5.09 Million - $7.42 Million	-320,866 Reduced 22.0%	1,137,287 $24.5 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $16.7 Million - $35.8 Million	-988,110 Reduced 40.39%	1,458,153 $26.6 Million
Q2 2019 Jul 31, 2019	SELL	$31.0 - $36.3 $514,507 - $602,471	-16,597 Reduced 0.67%	2,446,263 $87 Million
Q1 2019 Apr 30, 2019	SELL	$31.58 - $46.35 $2.02 Million - $2.97 Million	-64,101 Reduced 2.54%	2,462,860 $82.8 Million
Q4 2018 Feb 06, 2019	SELL	$30.43 - $56.65 $61.1 Million - $114 Million	-2,009,037 Reduced 44.29%	2,526,961 $83.1 Million
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $16.7 Million - $24.7 Million	-359,970 Reduced 7.35%	4,535,998 $277 Million
Q2 2018 Aug 10, 2018	SELL	$46.25 - $104.45 $17.9 Million - $40.4 Million	-386,843 Reduced 7.32%	4,895,968 $239 Million
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $84.8 Million - $160 Million	1,477,497 Added 38.83%	5,282,811 $561 Million
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $11 Million - $28.8 Million	476,033 Added 14.3%	3,805,314 $227 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $27.7 Million - $37.4 Million	1,556,352 Added 87.78%	3,329,281 $0
Q2 2017 Aug 17, 2017	BUY	N/A	1,772,929	1,772,929 $34.7 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account